Hriday P Bhambhvani1, Daniel R Greenberg2, Sandy Srinivas3, Melanie Hayden Gephart4. 1. Department of Neurosurgery, Stanford University Medical Center, Stanford, California, USA. 2. Department of Urology, Stanford University Medical Center, Stanford, California, USA. 3. Division of Medical Oncology, Stanford University Medical Center, Stanford, California, USA. 4. Department of Neurosurgery, Stanford University Medical Center, Stanford, California, USA. Electronic address: mghayden@stanford.edu.
Abstract
BACKGROUND: Brain metastases from prostate cancer are rare and poorly described. We sought to assess the proportion of brain metastases arising from prostate cancer and to detail clinical characteristics, treatment modalities, and survival outcomes. METHODS: We retrospectively identified and reviewed the charts of 31 patients with intraparenchymal brain metastases from prostate adenocarcinoma seen at our institution from 2008 to 2018. RESULTS: Among all patients with brain metastases, the proportion originating from prostate adenocarcinoma was 0.86%. The median age at the time of brain metastasis diagnosis was 69 (range, 57-90). The median original Gleason score was 8 (range, 6-10), and the median prostate-specific antigen at the time of brain metastasis was 60 ng/mL (range, 0.34-4600). The median months from initial cancer diagnosis to brain metastasis was 81 (range, 3-195). The median number of brain metastases was 2 (range, 1-5). Patients had concurrent metastases to bone (100%), lung (48%), and liver (35%). Median overall survival was 3 months (range, 0.4-25.0). Treatment of the brain metastases was correlated with an increase in median survival from 1.2 months to 4.6 months with radiosurgery (hazard ratio = 0.11, P = 0.001) and surgical resection plus radiotherapy to 13 months (hazard ratio = 0.05, P < 0.001). All patients died of advanced, systemic disease and not of their intracranial disease. CONCLUSIONS: Brain metastasis from prostate cancer constitutes a small fraction of total brain metastases, but is associated with poor prognosis and is seen in the setting of advanced, castrate resistant disease. These data enable treating physicians to appropriately counsel their patients with prostate adenocarcinoma brain metastasis.
BACKGROUND:Brain metastases from prostate cancer are rare and poorly described. We sought to assess the proportion of brain metastases arising from prostate cancer and to detail clinical characteristics, treatment modalities, and survival outcomes. METHODS: We retrospectively identified and reviewed the charts of 31 patients with intraparenchymal brain metastases from prostate adenocarcinoma seen at our institution from 2008 to 2018. RESULTS: Among all patients with brain metastases, the proportion originating from prostate adenocarcinoma was 0.86%. The median age at the time of brain metastasis diagnosis was 69 (range, 57-90). The median original Gleason score was 8 (range, 6-10), and the median prostate-specific antigen at the time of brain metastasis was 60 ng/mL (range, 0.34-4600). The median months from initial cancer diagnosis to brain metastasis was 81 (range, 3-195). The median number of brain metastases was 2 (range, 1-5). Patients had concurrent metastases to bone (100%), lung (48%), and liver (35%). Median overall survival was 3 months (range, 0.4-25.0). Treatment of the brain metastases was correlated with an increase in median survival from 1.2 months to 4.6 months with radiosurgery (hazard ratio = 0.11, P = 0.001) and surgical resection plus radiotherapy to 13 months (hazard ratio = 0.05, P < 0.001). All patientsdied of advanced, systemic disease and not of their intracranial disease. CONCLUSIONS: Brain metastasis from prostate cancer constitutes a small fraction of total brain metastases, but is associated with poor prognosis and is seen in the setting of advanced, castrate resistant disease. These data enable treating physicians to appropriately counsel their patients with prostate adenocarcinoma brain metastasis.
Authors: Tyler Cardinal; Dhiraj Pangal; Ben A Strickland; Paul Newton; Saeedeh Mahmoodifar; Jeremy Mason; David Craig; Thomas Simon; Ben Yi Tew; Min Yu; Wensha Yang; Eric Chang; Ryan P Cabeen; Jacob Ruzevick; Arthur W Toga; Josh Neman; Bodour Salhia; Gabriel Zada Journal: Neurooncol Adv Date: 2021-11-18
Authors: Kobisha Rajeswaran; Kaitlin Muzio; Juan Briones; Mary Jane Lim-Fat; Chia-Lin Tseng; Martin Smoragiewicz; Jay Detsky; Urban Emmenegger Journal: J Clin Med Date: 2022-07-18 Impact factor: 4.964